A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment

We recently demonstrated that obinutuzumab (GA101), a novel glycoengineered type II CD20 Ab compared to rituximab (RTX) mediates significantly enhanced antibody-dependent cell cytotoxicity (ADCC) in vitro and increased overall survival in a Burkitt lymphoma (BL) xenograft non-obese diabetic severe c...

Descripción completa

Detalles Bibliográficos
Autores principales: Awasthi, Aradhana, Rolland, Delphine C.M., Ayello, Janet, van de Ven, Carmella, Basrur, Venkatesha, Conlon, Kevin, Fermin, Damian, Barth, Matthew J, Klein, Christian, Elenitoba-Johnson, Kojo S.J., Lim, Megan S., Cairo, Mitchell S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768372/
https://www.ncbi.nlm.nih.gov/pubmed/29371955
http://dx.doi.org/10.18632/oncotarget.23040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768372/
https://www.ncbi.nlm.nih.gov/pubmed/29371955
http://dx.doi.org/10.18632/oncotarget.23040

Ejemplares similares